Pennsylvania is currently home to 3316 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677
Recruiting
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Saint Vincent Hospital, Erie, Pennsylvania
Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Register for Updates
Flu Infection at UPHS
NCT06807840
Recruiting
Cellular and humoral immune responses in individuals with active influenza infection will be assessed. Each year, up to 50 participants will be enrolled. The investigators hypothesize that influenza infection will elicit mostly memory immune responses rather than de novo immune responses to infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
Conditions: Influenza Human
Register for Updates
Patient Navigation to Improve Surgical Access in Primary Hyperparathyroidism
NCT06562881
Recruiting
The goal of this study is to address surgical health equity in historically marginalized participants with primary hyperparathyroidism (PHPT). The main questions that this study aims to answer are, how does patient navigation impact: * The proportion of PHPT participants undergo parathyroidectomy? * The proportion of PHPT participants who complete surgical consultation? * Time to surgical consultation? * Time to surgery?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Hyperparathyroidism, Primary
Register for Updates
Ketogenic Diet in Healthy Adults With Differing BMI
NCT06515912
Recruiting
The goal of this clinical trial is to examine the effect of the ketogenic diet over four weeks on blood lipid levels and risk factors for heart disease in adults with a healthy BMI compared to adults with a body mass index (BMI) in the range for obesity. The main questions it aims to answer are: * Does the ketogenic diet cause larger increases in "bad cholesterol" (low density lipoprotein-cholesterol) in adults with a healthy BMI compared to adults with BMI in the range for obesity? * Does the... Read More
Gender:
ALL
Ages:
Between 25 years and 45 years
Trial Updated:
01/29/2025
Locations: Penn State University, University Park, Pennsylvania
Conditions: Cardiovascular Diseases
Register for Updates
Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer
NCT06388018
Recruiting
This phase II trial tests how well tailoring therapy in post-surgery works in patients with low-risk endometrial cancer. The usual approach for patients with low-risk endometrial cancer is treatment with surgery. In this study, tissue that is removed as part of the surgical procedure is analyzed in the pathology laboratory to help guide the doctor to decide whether or not additional treatment such as radiation and or chemotherapy should be recommended.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania
Conditions: Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC V8, Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC V8, Stage III Uterine Corpus Endometrial Stromal Sarcoma AJCC V8
Register for Updates
Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT06175065
Recruiting
AECOPD is a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity, and quality of life (QoL). RLS-0071 is a novel peptide being developed for the treatment of AECOPD. This study is designed to evaluate the safety and tolerability of RLS-0071 in the treatment of adults with moderate exacerbations of COPD.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
01/29/2025
Locations: Site 01, Philadelphia, Pennsylvania
Conditions: Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Register for Updates
A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors (OASIS)
NCT06063317
Recruiting
This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab in adults with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Solid Tumor, Adult
Register for Updates
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
NCT05995535
Recruiting
A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of Pennsylvania, Treatment Research Center, Philadelphia, Pennsylvania
Conditions: Opiate Withdrawal Syndrome, Opioid Use
Register for Updates
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
NCT05964504
Recruiting
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Metastatic Breast Cancer, Lobular Breast Carcinoma
Register for Updates
Study of Tucatinib and Doxil in Participants with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT05748834
Recruiting
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Alliance Cancer Specialists, Bensalem, Pennsylvania
Conditions: Breast Cancer
Register for Updates
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
NCT05496036
Recruiting
The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence. Another purpose of this study is to look at the side effects that occur when the experimental drug pembrolizumab is given to people with Merkel cell carcinoma before and after their standard of care surgery to remove the Merkel cell carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Penn Medicine, Philadelphia, Pennsylvania
Conditions: Merkel Cell Carcinoma
Register for Updates
Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)
NCT05482893
Recruiting
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, and pancreatic ductal adenocarcinoma (PDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania
Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Register for Updates